WCLC 2020: Updates in EGFR Exon 20-Targeted Therapies | Supplements And Featured Publications

Heymach Homes in On Emerging Agents in EGFR Exon 20–Mutant NSCLC

March 04, 2021

John V. Heymach, MD, PhD, discusses the incidence of EGFR exon 20 insertions in lung cancer, diagnostic challenges of identifying EGFR exon 20 insertions, and data from the International Association for the Study of Lung Cancer 2020 World Conference on Lung Cancer with mobocertinib and amivantamab in this patient subset.

Mobocertinib Shows Encouraging ORR in EGFR Exon 20–Mutant Advanced NSCLC

January 30, 2021

January 29, 2021 — Mobocertinib (formerly TAK-788) demonstrated clinically meaningful benefit and a manageable safety profile in previously treated patients with metastatic non–small cell lung cancer who have EGFR exon 20 insertion mutations.

x